

WELCOME NOTE



Dear Ladies and Gentlemen,
Dear Colleagues,

We herewith cordially invite you to the 14th Congress of the European Headache Society in Berlin.

New and exciting times are dawning, with a slew of new therapies underway: CGRP antibodies for migraine prophylaxis, lasmiditan as an alternative to triptans for acute therapy, atogepant, ubrogepant, possibly PACAP antibodies and more. That is why we chose “*Head over Ache - Silver Lining Novel Treatments*” for the motto of the 14th European Headache Federation Congress.

Now we, physicians, psychologists, cost bearers, politicians, and those working in health care, must make sure that the new as well as the old treatments reach the right patients in the optimal way.

We therefore invite doctors and scientists from Europe and abroad, but also our partners EFIC, EAN, WONCA, EMA, and WHO to take part in this event. The scientific committee will be co-chaired by Professor Richard Lipton, US.


We warmly welcome you to the Maritim Hotel from **26–28 June 2020** in wonderful **Berlin**, which is always worth a visit, especially at the beginning of summer! Together, let’s explore the future of headache treatment here in the capital of Germany. I remain in anticipation of interesting contributions and a profitable discussion,

Yours sincerely,

Zaza Katsarava
President EHF & Congress chair EHF 2020

EHF 2020

Head over Ache –
Silver Lining Novel
Treatments



14th
European Headache Federation
Congress

26–28 June 2020
Berlin | Germany

SAVE THE DATE

PROGRAMME AND TOPICS

New treatments

Impact of CGRP targeted therapies in practice: Evidence from clinical trials and clinical practice

Overview of approved and soon to be approved preventive treatments, real-world evidence on patterns of use and impact on outcomes

New targets

Emphasizes the generation of mechanisms that will lead to the next generation of treatment

Prognostic biomarkers and individualized treatment

Identifying natural subgroups of people with migraine: Approaches to personalized medicine

Review on the evidence that symptom profiles, comorbidity, triggers, treatment response, genetics, biomarkers and imaging can be used to identify natural subgroups of people with migraine and that those subgroups are useful in individualizing treatment and improving outcomes

Headache and public health

Measuring the interictal burden of migraine, WHO perspectives

Regulatory and reimbursement science in headache medicine

EMA, FDA, NICE perspectives

Role of MBS as an acute treatment outcome

Latest and greatest headache science

Role of glymphatic system in migraine, mechanisms of individual symptoms such as nausea, photo, phono, etc.

Young scientific talents

EHF – School of Advanced Studies presents its work

EHF invites:

EFIC – European Pain Federation

WONCA – World Organization of National Colleges

Academies and Academic Associations of General

Practitioners/Family Physicians

EMA – European Medicines Agency

WHO – World Health Organization

to talk about headache

GENERAL INFORMATION

Venue

Maritim Hotel Berlin

Stauffenbergstraße 26 | 10785 Berlin, Germany

Congress Website

www.ehf2020.com

Scientific Committee

Chairs

Professor Zaza Katsarava

Chief, Department of Neurology

Evangelical Hospital Unna, Germany

Professor of Neurology

Medical Faculty, University of Essen, Germany

Professor Richard B. Lipton

Director, Division of Cognitive Aging and Dementia

Director, Montefiore Headache Center

Albert Einstein College of Medicine

New York, US

Industrial Exhibition

Interested companies are invited to request information on the sponsor and exhibition modalities from the congress organization Conventus.

Professional Congress Organizer

Conventus Congressmanagement & Marketing GmbH

Phone +49 3641 31 16-406

ehf2020@conventus.de | www.conventus.de